Multiple Sclerosis Treatment Devices Market

Multiple Sclerosis Treatment Devices Market Overview

The Multiple Sclerosis Treatment Devices Market was valued at USD 0.85 Billion in 2024. The Multiple Sclerosis Treatment Devices Market industry is projected to grow from USD 0.88 Billion in 2025 to USD 1.46 Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 9.0% during the forecast period (2025-2035).

The increasing prevalence of multiple sclerosis (MS) advancements in neurostimulation and wearable are driving the growth of the Multiple Sclerosis Treatment Devices Market.

As per the Analyst at MRFR, the disease is significantly more common in women, with a female-to-male ratio of nearly 3:1, further influencing market trends as gender-specific treatment approaches gain traction. The increasing prevalence of MS is fueling demand for advanced treatment solutions, including neurostimulation devices, wearable rehabilitation technologies, and others, which help manage symptoms such as spasticity, gait disorders, and chronic pain. 

Biomarkerlly, improved diagnostic capabilities due to advancements in imaging techniques like MRI-based lesion tracking and biomarker research are leading to earlier and more accurate diagnoses, further driving the adoption of treatment devices. The rising global MS burden has also led to increased healthcare investments, government initiatives, and funding for innovative medical technologies, positioning the MS treatment devices market for sustained growth.

FIGURE 1: MULTIPLE SCLEROSIS TREATMENT DEVICES MARKET VALUE (2019-2035) USD BILLION

 Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Multiple Sclerosis Treatment Devices Market Opportunity

RISING COLLABORATIONS BETWEEN HEALTHCARE PROVIDERS AND TECHNOLOGY FIRMS

The rising collaborations between healthcare providers and technology firms are playing a crucial role in advancing Multiple Sclerosis (MS) treatment devices, leading to more effective, accessible, and patient-centric treatment solutions. As MS is a chronic neurological disorder with progressive symptoms affecting mobility, muscle control, and neurological function, partnerships between hospitals, medical device manufacturers, and health-tech companies are driving innovation in neurostimulation, rehabilitation, and assistive treatment devices that improve patient outcomes.

One of the essential fields of cooperation is developing next generation neurostimulation devices. Healthcare providers are in close collaboration with medical technology firms specializing in spinal cord stimulation, transcranial magnetic stimulation, and vagus nerve stimulation to explore non-invasive and implantable neurostimulation therapies for MS patients. Collaborations are also driving innovation in wearable functional electrical stimulation (FES) devices, which assist MS patients with gait and mobility challenges. Medical device manufacturers are working alongside rehabilitation specialists and physiotherapists to develop smart FES systems that deliver targeted electrical impulses to weak or paralyzed muscles, improving walking ability. For example, companies like Bioness and Ottobock have partnered with neurology-focused rehabilitation centers to introduce intelligent, sensor-based FES leg braces that adapt to a patient’s movement patterns in real time, enhancing muscle coordination and reducing the risk of falls.

Another significant achievement that has resulted from technology-healthcare partnerships is the integration of AI-driven digital treatment platforms in MS therapy. Companies specializing in AI-based neuromodulation and remote therapy management are teaming up with neurology clinics to develop real-time patient monitoring solutions that can track disease progression and adjust the parameters of the treatment accordingly. For instance, NeuroMetrix, in collaboration with leading MS specialists, has developed Quell, a wearable neuromodulation device that provides adjustable, AI-driven pain relief therapy for MS patients suffering from chronic pain and muscle discomfort.

Such partnerships are transforming the landscape of MS treatments, with all patients accessing up-to-date neurostimulation, rehabilitation, and assistive treatment devices, enhancing quality of life. Increasing the adoption of AI-driven, cloud-connected, and wearable treatment devices will have health care providers and technology companies continuously working to present innovative, cost-effective, and patient-friendly solutions for the global market of MS treatments.

Multiple Sclerosis Treatment Devices Market Segment Insights

Multiple Sclerosis Treatment Devices by Type Insights

Based on Type, this segment includes Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Relapsing-remitting Multiple Sclerosis (RRMS), Clinically Isolated Syndrome (CIS). The Relapsing-remitting Multiple Sclerosis (RRMS) segment dominated the global market in 2024, while the Primary Progressive Multiple Sclerosis (PPMS) segment is projected to be the fastest–growing segment during the forecast period. 

However, the PPMS segment is expected to witness the fastest growth during the forecast period. This growth is attributed to increasing awareness, advancements in diagnostic techniques, and the launch of novel therapies targeting progressive forms of MS. As treatment options evolve, demand for targeted PPMS solutions is anticipated to rise significantly.

FIGURE 2: MULTIPLE SCLEROSIS TREATMENT DEVICES MARKET SHARE BY TYPE 2024 AND 2035 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Multiple Sclerosis Treatment Devices by Treatment Devices Insights

Based on Treatment Devices, this segment includes Electrical Stimulation Devices (Functional Electrical Stimulation (FES) and Transcutaneous Electrical Nerve Stimulation (TENS)), Neurostimulation Devices (Spinal Cord Stimulation (SCS) and Deep Brain Stimulation (DBS)). The Electrical Stimulation Devices segment dominated the global market in 2024, while it is projected to be the fastest–growing segment during the forecast period. These devices enhance mobility and improve quality of life for patients, which has driven their widespread acceptance in both clinical and home care settings. 

Furthermore, this segment is projected to be the fastest-growing during the forecast period, supported by technological advancements, increased investment in neuro-rehabilitation, and rising awareness of non-pharmacological interventions. Compared to neurostimulation devices, electrical stimulation offers a cost-effective and accessible treatment option, contributing to its rapid growth and expanding role in MS symptom management.

Multiple Sclerosis Treatment Devices by End-User Insights

Based on the End-User, this segment includes Hospitals & Clinics and Ambulatory Surgical Centers. The Hospitals & Clinics segment dominated the global market in 2024, while the Ambulatory Surgical Centers segment is projected to be the fastest–growing segment during the forecast period. Hospitals and clinics serve as primary centers for diagnosis, therapy initiation, and long-term management of multiple sclerosis, driving consistent demand. 

However, the Ambulatory Surgical Centers (ASCs) segment is projected to be the fastest growing during the forecast period. This growth is fueled by the rising preference for minimally invasive procedures, shorter recovery times, and reduced healthcare costs associated with ASCs. Increasing patient inclination toward outpatient care and advancements in portable treatment device technologies further support the rapid expansion of this segment in the coming years.

Multiple Sclerosis Treatment Devices Regional Insights

Based on the Region, the global Multiple Sclerosis Treatment Devices are segmented into North America, Europe, Asia-Pacific, South America and Middle East & Africa. The Europe dominated the global market in 2024, while the Asia-Pacific is projected to be the fastest–growing segment during the forecast period. Major demand factors driving the Europe market are the increasing prevalence of multiple sclerosis (MS) advancements in neurostimulation and wearable. 

Europe dominated the global Multiple Sclerosis (MS) Treatment Devices market due to its advanced healthcare infrastructure and rising prevalence of MS. The region benefits from strong investments in research and development, along with the growing adoption of innovative neurostimulation and wearable technologies. These advancements support more effective symptom management and improve patient quality of life, driving market growth. Government initiatives and increased awareness of early diagnosis and treatment options also contribute to Europe’s leading position.

FIGURE 3: MULTIPLE SCLEROSIS TREATMENT DEVICES MARKET VALUE BY REGION 2024 AND 2035 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Further, the countries considered in the scope of the Application Tracking System Market are the US, Canada, Germany, France, UK, Spain, Italy, Russia, China, India, Japan, South Korea, Malaysia, Thailand, Indonesia, Brazil, Mexico, Argentina, GCC Countries, South Africa and others.

Global Multiple Sclerosis Treatment Devices Key Market Players & Competitive Insights

Many global, regional, and local vendors characterize the Multiple Sclerosis Treatment Devices Market. The market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market.

The major competitors in the market are Enovis, Axonics, Inc., Koninklijke Philips N.V., BTL, Bayer AG, Medtronic, Abbott, Boston Scientific Corporation, Biotronik, Saluda Medical Pty Ltd are among others. The Multiple Sclerosis Treatment Devices Market is a consolidated market due to increasing competition, acquisitions, mergers and other strategic market developments and decisions to improve operational effectiveness.

Key Companies in the Multiple Sclerosis Treatment Devices Market include

• Enovis
• Axonics, Inc.
• Koninklijke Philips N.V.
• BTL
• Bayer AG
• Medtronic
• Abbott
• Boston Scientific Corporation
• Biotronik
• Saluda Medical Pty Ltd

Multiple Sclerosis Treatment Devices Market Industry Developments

August 2024: The FDA has recently approved Medtronic’s closed-loop rechargeable spinal cord stimulator (SCS). This approval makes Inceptiv the first SCS device on the market with a closed-loop feature that continuously senses biological signals along the spinal cord and automatically adjusts stimulation in real time, ensuring therapy remains synchronized with patients' daily activities.

April 2023: Biotronik announced that it received FDA approval for its Prospera Spinal Cord Stimulation (SCS) system, which features Resonance, a multiphase stimulation paradigm. The system is paired with Embrace One, a patient-centric care model that offers automatic, objective, daily remote monitoring.

January 2021: Boston Scientific launched the WaveWriter Alpha Spinal Cord Stimulator (SCS) Systems in the U.S., offering a comprehensive portfolio of four MRI-conditional, Bluetooth-enabled implantable pulse generators (IPGs). Available in both rechargeable and non-rechargeable options.

Multiple Sclerosis Treatment Devices Market Segmentation

Multiple Sclerosis Treatment Devices by Type Outlook

• Primary Progressive Multiple Sclerosis (PPMS)
• Secondary Progressive Multiple Sclerosis (SPMS)
• Relapsing-remitting Multiple Sclerosis (RRMS)
• Clinically Isolated Syndrome (CIS)

Multiple Sclerosis Treatment Devices by Treatment Devices Outlook

• Electrical Stimulation Devices
  • Functional Electrical Stimulation (FES)
  • Transcutaneous Electrical Nerve Stimulation (TENS)
• Neurostimulation Devices
  • Spinal Cord Stimulation (SCS)
  • Deep Brain Stimulation (DBS)

Multiple Sclerosis Treatment Devices by End-User Outlook

• Hospitals & Clinics
• Ambulatory Surgical Centers                                                                                                

Multiple Sclerosis Treatment Devices Regional Outlook

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Russia
  • Rest of Europe
• Asia-pacific
  • China
  • India
  • Japan
  • South Korea
  • Malaysia
  • Thailand
  • Indonesia
  • Rest of Asia-Pacific
• South America
  • Brazil
  • Mexico
  • Argentina
  • Rest of South America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of MEA